Myelodysplastic Syndromes

Our specialists provide expert care for people with myelodysplastic syndromes (MDS). These are conditions in which the blood-forming cells in the bone marrow are damaged, leading to a decreased number of red blood cells, white blood cells, or platelets. We use sophisticated testing to identify the type of MDS and determine the risk of the condition progressing. Then, we create a personalized and evidence-based treatment plan to meet your needs, ranging from watchful monitoring to stem cell transplantation.

Clinical Trials and Research Studies

Phase 3

A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Learn More

Phase 2

AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Learn More

Phase 3

AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Learn More

Phase 3

A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)

Learn More